BirteWistinghausenMD

Pediatric Hematology & Oncology • Washington, DC

Pediatric Hematologic Oncology

Oncology Medical Unit Director

Join to view full profile

Dr. Wistinghausen is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Wistinghausen's full profile

Already have an account?

Office
Children's National Medical Center
111 Michigan Ave NW
Washington, DC 20010
Phone+1 202-476-2800

Education & Training

NYU Grossman School of MedicineFellowship, Pediatric Hematology/Oncology, 1999 - 2001
NYU Grossman School of MedicineResidency, Pediatrics, 1996 - 1999
University of Kiel Faculty of MedicineClass of 1993

Certifications & Licensure

MD State Medical License 2018 - 2025
NY State Medical License 1999 - 2025
DC State Medical License 2018 - 2024
PA State Medical License 2015 - 2022
ME State Medical License Active through 2003
American Board of Pediatrics Pediatric Hematology-Oncology

Awards, Honors, & Recognition

Top Doctors: New York Metro Area Castle Connolly, 2014
New York Magazine: Top Doctors Castle Connolly, 2013-2014
Best Doctors, Pediatric Hematology-Oncology New York Magazine, 2013-2015
Fellow, Institute of Medical Education Icahn School of Medicine at Mount Sinai, 2011
First Sydney Q. Cohlan Resident and Fellow Research Award, Department of Pediatrics New York University Medical Center, 2001
Join now to see all

Clinical Trials

Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma Start of enrollment: 2001 Oct 18
Active, not recruiting
Phase 3
Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma Start of enrollment: 2004 Sep 04
Completed
Phase 3
Combination Chemotherapy, PEG-Interferon Alfa-2b, and Surgery in Treating Patients With Osteosarcoma Start of enrollment: 2005 Nov 14
Completed
Phase 3
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant Start of enrollment: 2006 Apr 01
Completed
Phase 2
Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor Start of enrollment: 2006 Nov 06
Active, not recruiting
Phase 3
Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma Start of enrollment: 2006 Dec 26
Completed
Phase 3
Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia Start of enrollment: 2007 Mar 01
Completed
Phase 1, Phase 2
Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia Start of enrollment: 2007 Mar 01
Completed
Phase 3
Tacrolimus and Methotrexate With or Without Sirolimus in Preventing Graft-Versus-Host Disease in Young Patients Undergoing Donor Stem Cell Transplant for Acute Lymphoblastic Leukemia in Complete Remission Start of enrollment: 2007 Mar 01
Completed
Phase 3
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma Start of enrollment: 2007 Jan 22
Active, not recruiting
Phase 3
The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients Start of enrollment: 2007 Sep 01
Completed
Not Applicable
Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies Start of enrollment: 2008 Jul 17
Recruiting
Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer Start of enrollment: 2003 Oct 13
Completed
Study of Kidney Tumors in Younger Patients Start of enrollment: 2006 Feb 27
Recruiting
Collecting and Storing Samples of Blood and Tumor Tissue From Patients With Osteosarcoma Start of enrollment: 2008 Feb 04
Completed
Collecting and Storing Biological Samples From Patients With Ewing Sarcoma Start of enrollment: 2008 Feb 04
Completed
Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma Start of enrollment: 2000 Nov 06
Recruiting
Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Soft Tissue Sarcoma Start of enrollment: 1999 Mar 15
Completed
Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor Start of enrollment: 2009 Jul 13
Active, not recruiting
Phase 3
Risk-Based Classification System of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Start of enrollment: 2010 Aug 09
Completed
Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma Start of enrollment: 2010 Aug 09
Active, not recruiting
Phase 3
Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma Start of enrollment: 2010 Nov 22
Active, not recruiting
Phase 3
Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2011 Jun 20
Active, not recruiting
Phase 3
A Phase III Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND# 73789, NSC# 606869) in the Very High Risk Stratum Start of enrollment: 2012 Feb 01
Intergroup Trial for Children or Adolescents With B-Cell NHL or B-AL: Evaluation of Rituximab Efficacy and Safety in High Risk Patients Start of enrollment: 2012 Jun 01
Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive, CD20-Positive Post-Transplant Lymphoproliferative Disorder Start of enrollment: 2017 Mar 22
Active, not recruiting
Phase 2
Use Of A Response-Adapted Ruxolitinib-Containing Regimen For The Treatment Of Hemophagocytic Lymphohistiocytosis Start of enrollment: 2021 Jul 13
Recruiting
Phase 1, Phase 2
Roles: Contact, Principal Investigator
Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders Start of enrollment: 2021 Apr 19
Recruiting
Phase 2
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

15 citations
Diagnostic challenges in a child with familial hemophagocytic lymphohistiocytosis type 3 (FHLH3) presenting with fulminant neurological disease
James D. Weisfeld-Adams, Yitzchak Frank, Vinod Havalad, Joanne M. Hojsak, Roberto Posada
Child's Nervous System. 2009-02-01
2 citations
Durable immunity to EBV after rituximab and third-party LMP-specific T cells: a Children's Oncology Group study.
Birte Wistinghausen, Keri Toner, Donald A Barkauskas, Lauren P Jerkins, Hannah Kinoshita
Blood Advances. 2024-03-12
37 citations
Post-Transplant Lymphoproliferative Disease in Pediatric Solid Organ Transplant Recipients
Birte Wistinghausen, Thomas G. Gross, Catherine M. Bollard
Pediatric Hematology and Oncology. 2013-08-13

Journal Articles

Identifying Predictive Factors for Post-Transplant Lymphoproliferative Disease (PTLD) in Pediatric Solid Organ Trasplant (SOT) Recipients with Epstein-Barr Virus (EBV)...
Weintraub L, Weiner C, Miloh T, Tomaino J, Joashi U, Benchimol C, Strauchen J, Wistinghausen B, J Pediatr Hematol Oncol, 1/1/2014
Post-transplant Lymphoproliferative Disease
Wistinghausen B, Gross TG, Bollard CM, Pediatric Hematology-Oncology, 1/1/2013
Graft rejection in pediatric liver transplant patients with EBV viremia and PTLD
Weiner C, Weintraub L, Wistinghausen B, Arnon R, Kerkar N, Miloh T, Pediatr Transplant, 1/1/2012
Long-term remission in a child with refractory EBV(+) hydroa vacciniforme-like T-cell lymphoma through sequential matched EBV(+)-related allogeneic hematopoietic SCT f...
El-Mallawany NK, Gellert L, Bollard CM, Wistinghausen B, Mussai F, Wayne AS, Alobeid B, Cairo MS, Bone Marrow Transplant, 1/1/2011
Severe factor XI deficiency in an Arab family associated with a novel mutation in exon XI
Wistinghausen B, Reischer A, Oddoux C, Ostrer H, Nardi M, Karpatkin M, British Journal of Hematology, 1/1/1997
Join now to see all

Abstracts/Posters

A Lymphomatous Presentation of Mixed Lineage T/Myeloid Leukemia.
Minkowitz S, Davis J, Petersen B, Wistinghausen B, 5th International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin Lymphoma, Varese, Italy, 1/22/2015
A Case Series of Adolescent Bone Lymphoma.
Wistinghausen B, Davis J, 5th International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin Lymphoma, Varese, Italy, 1/22/2015
Remission Induction in Mixed Lineage T/Myeloid Leukemia with Clofarabine in Patients who Fail ALL-type Therapy Followed by Hematopoietic Stem Cell Transplantation.
Minkowitz S, Davis J, Petersen B, Wistinghausen B, International Society of Pediatric Oncology (SIOP) Meeting, Capetown, South Africa, 1/1/2015
Two cases of neonatal disseminated juvenile xanthogranulomatosis treated with LCH-based therapy.
Thomas YE, Kirschner D, Phelps RG, Rosenberg H, Merola P, Wistinghausen, B, Pediatr Blood and Cancer, 1/1/2014
Effects of retinoic acid on the growth of a medulloblastoma cell line.
Wistinghausen B, Herman Yee And Kenichi Takeshita, World Federation of Neuro-Oncology Societies/ Society for Neuro-Oncology Sixth Annual Meeting, 1/1/2001
Severe factor XI deficiency in an Arab family associated with a novel mutation in Exon XI.
Wistinghausen B, Reischer A, Nardi M and Karpatkin M, XVIth congress of the International Society of Thrombosis and Hemostasis., Florence, Italy, 1/1/1997
Immunoscintigraphy in the follow-up of patients with colorectal carcinoma using the Indium-111 monoclonal antibody (MAB) B72.3.
Clausen M, Wistinghausen B, Schubert U, Schramm M, Wolf H, Schmuecking M, Bohuslavizki K, Brenner W, Eberhardt J, Stauch C, Kovacs G, Kimmig B, Henze E, European Congress of Nuclear Medicine, 1/1/1993
Pharmakokinetics of the monoclonal antibody B72.3 in patients with colorectal carcinoma (Pharmakokinetik des monoklonalen Antikoerpers B72.3 bei Patienten mit kolorekt...
Clausen M, Wistinghausen B, Schubert U, Wolf H, Eberhardt J, Schmuecking M, Brenner W, Schramm M, Kovacs G, Kimmig B, Henze E, International Congress of the German Society of Nuclear Medicine, 1/1/1993
The radioimmunoscintigraphy in follow-up of colorectal carcinomas with the indium-111-labelled monoclonal antibody B72.3 (Die Radioimmunszintigraphie in der Nachsorge...
Wistinghausen B, Clausen M, Schubert U, Wolf H, Eberhardt J, Schmuecking M, Brenner W, Schramm M, Kovacs G, Kimmig B, Henze E, Internationale Congress of the German Society of Nuclear Medicine, 1/1/1993
Identifying Predictive Factors for Post-Transplant Lymphoproliferative Disease (PTLD) in Pediatric Solid Organ (SOT) recipients with Epstein-Barr virus (EBV) Viremia (...
Weintraub L, Weiner C, Miloh T, Tomaino J, Joashi U, Benchimol C, Strauchen J, Wistinghausen B, Pediatric Blood and Cancer
Join now to see all

Lectures

Hematology and Oncology Disorders and Complications affecting the GI Tract: Part I
Icahn School of Medicine, New York, NY - 1/30/2015
Implications of Post-Transplant Lymphoproliferatived Disease in Pediatric Solid Organ Recipients
Hackensack University Hospital, Hackensack, NJ - 1/23/2015
Diagnosis and Treatment of Childhood and Adolescent B-Lymphoblastic Lymphoma.
Varese, Italy - 1/22/2015
PTLD in Solid Organ Transplant Recipients: An Infectious, Immunological or Oncological Disease?
Children’s National Medical Center, Washington, DC - 1/17/2015
Acute Lymphoblastic Leukemia in Childhood
Brooklyn Hospital Medical Center - 1/24/2014
Presentation of protocol concept ANHL1421 for the treatment of pediatric patient with PTLD with rituximab and LMP CTLs
Dallas, TX - 1/17/2014
Update on Pediatric Post-Transplant Lymphoproliferative Disease in Solid Organ Recipients
Rutgers University Medical Center, New Brunswick, NJ - 1/21/2013
Post-Transplant Lymphoproliferative Disease in Pediatric Solid Organ Recipients
New Medical College, Valhalla, NY - 1/21/2013
Pediatric Lymphoma
Queens Hospital Center, New York, NY - 1/15/2013
Progress Report of AALL0932 arms B-LLy and Down B-LLy, a phase III protocol for the treatment of patients with stage I and II B-lymphoblastic lymphoma.
Minneapolis, MN - 1/12/2013
PTLD Protocol Development
Dallas, TX - 1/9/2013
Update on AALL0932, Lymphoblastic Lymphoma Arm
Dallas, TX - 1/9/2013
Pediatric Acute Lymphoblastic Leukemia
Bronx Lebanon Medical Center, Bronx, NY - 1/5/2013
Concept for a clinical protocol using rituximab and EBV-specific T-lymphocytes for the treatment of post-transplant lymphoproliferative disease in solid organ recipients.
Atlanta, GA - 1/12/2012
AALL0932, Amendment II: Inclusion of pediatric patients with localized B-lymphoblastic Lymphoma
Atlanta, GA - 1/12/2012
Post-Transplant Lymphoproliferative Disease
Mount Sinai School of Medicine, New York, NY - 1/5/2012
Pediatric Bone Tumors: Multi-disciplinary Approach to Diagnosis and Therapy
Mount Sinai School of Medicine, New York, NY - 1/15/2008
Medical Aspects of Liver Tumors
Mount Sinai School of Medicine, New York, NY - 1/12/2008
Post-Transplant Lymphoproliferative Disorder
Mount Sinai School of Medicine, New York, NY - 1/6/2007
The Effect of Retinoids on Medulloblastoma
New York University School of Medicine, New York, NY - 1/6/2003
T-cell leukemia and the SCL gene
New York University School of Medicine, New York, NY - 1/12/2000
A New Concept of Blood Coagulation and Factor XI Deficiency
New York University School of Medicine, New York, NY - 1/30/1997
Join now to see all

Press Mentions

Use of a Response-Adapted Ruxolitinib-Containing Regimen for the Treatment of Hemophagocytic LymphohistiocytosisSeptember 16th, 2020
Use of a Response-Adapted Ruxolitinib-Containing Regimen for the Treatment of Hemophagocytic LymphohistiocytosisJuly 27th, 2023
Asparaginase in ALL: Innovative Ways to Manage ToxicityFebruary 23rd, 2024

Professional Memberships

American Society of Clinical Oncology - ASCO
Member